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Osteoporosis is a complex disease that affects 110 million people in the United States and results in 1.5 million
fractures annually. In addition, the high prevalence of osteopenia (low bone mass) in the general population places
a large number of people at risk for developing the disease. In an effort to identify genetic factors influencing bone
density, we characterized a family that includes individuals who possess exceptionally dense bones but are otherwise
phenotypically normal. This high–bone-mass trait (HBM) was originally localized by linkage analysis to chro-
mosome 11q12-13. We refined the interval by extending the pedigree and genotyping additional markers. A sys-
tematic search for mutations that segregated with the HBM phenotype uncovered an amino acid change, in a
predicted b-propeller module of the low-density lipoprotein receptor–related protein 5 (LRP5), that results in the
HBM phenotype. During analysis of 11,000 individuals, this mutation was observed only in affected individuals
from the HBM kindred. By use of in situ hybridization to rat tibia, expression of LRP5 was detected in areas of
bone involved in remodeling. Our findings suggest that the HBM mutation confers a unique osteogenic activity in
bone remodeling, and this understanding may facilitate the development of novel therapies for the treatment of
osteoporosis.
Introduction
Bone is a dynamic organ that is constantly being de-
graded and renewed in a remodeling process. A tight
coupling between bone resorption by osteoclasts and
deposition by osteoblasts is therefore required to main-
tain normal skeletal structure. If this delicate balance is
disturbed, however, the density and architecture of bone
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can become abnormal, resulting in diseases such as os-
teoporosis or osteopetrosis (Marks and Hermey 1996).
Although environmental factors such as diet and exercise
clearly affect bone mineral density (BMD), it is also well
documented that genetic factors are involved (Blank
2001). In an effort to identify genes that play a role in
regulating BMD, we have elsewhere characterized a fam-
ily exhibiting an autosomal dominant trait of high bone
mass (HBM or BMND1 [MIM 601884]; Johnson et al.
1997). Linkage analysis showed that the trait was lo-
calized to a region of ∼30 cM betweenmarkersD11S905
and D11S937 on chromosome 11q12-13. Interestingly,
additional genetic loci that segregated with abnormal
bone phenotypes and that map to 11q13 include loci
for osteoporosis pseudoglioma syndrome (OPS [MIM
259770]; Gong et al. 1996) and autosomal recessive os-
teopetrosis (arOP [MIM 259700]; Heaney et al. 1998),
as well as a quantitative trait locus (QTL) that contrib-
utes to normal variation in bone mineral density (Koller
et al. 1998). OPS, a recessive disorder, is characterized
by premature osteoporosis that leads to bone fracture
and deformity and by congenital or juvenile-onset blind-
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ness. A subset of arOP cases results from mutations in
the osteoclast-specific TCIRG1 subunit of the vacuolar
proton pump (Frattini et al. 2000; Scimeca et al. 2000).
This results in defective resorption of immature bone by
osteoclasts and causes the abnormal accumulation of
excessive amounts of bone.
In the present study, we describe the refinement of
the HBM interval by extending the pedigree and ge-
notyping additional markers in the region. In addition,
we systematically searched for mutations that segre-
gated with the HBM phenotype and that were rare in
the general population. From these analyses, we iden-
tified a mutation, in the low-density lipoprotein recep-
tor–related protein 5 gene (LRP5), that results in the
HBM phenotype.
Material and Methods
Phenotyping
Spinal bone mineral content (BMC) and BMD mea-
surements were made by dual-energy X-ray absorptiom-
etry, using Hologic 2000 (Hologic) or Norland XR2600
(Norland Medical Systems) densitometers. The study
was approved by the appropriate institutional review
board; appropriate informed consent was obtained from
human subjects.
Genotyping
DNA was extracted from blood samples, using a kit
(Gentra Systems, Inc.). Genotyping was performed as
described elsewhere (Johnson et al. 1997). Markers sup-
plementing the original screening set in the critical in-
terval included D11S4191, D11S1296, D11S1337,
D11S970, D11S4113, D11S4136, and D11S4139 and
seven novel genetic markers developed from genomic
sequence. Microsatellite marker GTC271K22, a CA re-
peat that defined the telomeric boundary, was identified
from genomic sequence. Primers used for genotyping the
∼175-bp products were 5′-TTTTGGGTACACAATTC-
AGTCG-3′ (forward) and 5′-AAAACTGTGGGTGCTT-
CTGG-3′ (reverse).
Linkage Analysis
Multipoint and haplotype analyses were performed
using a modified version of the program SIMWALK2
(Sobel and Lange 1996) that allowed for the analysis of
quantitative traits. Affection status (qualitative pheno-
type) was defined as having a sum of hip and spine Z
scores 14 or having spine Z scores 12, among the three
individuals for whom hip BMD measurements were not
available. A quantitative phenotype was defined as the
sum of the hip and spine Z scores and as twice the spine
Z score when no hip score was available. Thirty-eight
individuals were genotyped and included in the linkage
analysis; phenotypic information was missing for one
individual who was too young to be phenotyped at the
time of the study. Marker-allele frequencies were esti-
mated by maximum likelihood (Boehnke 1991), and the
gene frequency was set at .0001. For the qualitative trait,
an autosomal dominant, fully penetrant model with a
phenocopy rate of 1% was used. We used maximum
likelihood estimates for a mixture of normal distribu-
tions to define our quantitative model. The mean of the
sum of the hip and spine Z scores for homozygous wild-
type individuals was estimated at 0.1 and that for het-
erozygotes was estimated at 8.4; the mean for hypo-
thetical individuals with two copies of the mutation was
set at 16.9, under the assumption of an additive model.
In addition, the variance for the trait was estimated at
1.9 for the homozygous groups and at 6.8 for the het-
erozygous group. Haplotype analysis was performed us-
ing the genotype only with SIMWALK2 and was visu-
alized with the Cyrillic program.
Gene Characterization
BAC clones containing sequence-tagged site (STS)
markers were obtained by PCR-based screening of DNA
pools from human BAC libraries (CITB, RPCI-11, and
Genome Systems). DNA pools corresponding to nine
genomic equivalents of human DNA were screened. Se-
quencing of BAC clones and BAC insert termini was
performed using standard ABI 377 automated DNA se-
quencing methods. Direct cDNA selection was per-
formed, as described elsewhere, using cDNA pools from
bone marrow, calvarial bone, femoral bone, kidney,
skeletal muscle, testis, and total brain (Del Mastro and
Lovett 1997). DNA from 54 BACs spanning the region
was isolated using Nucleobond AX columns (The Nest
Group), was pooled in equimolar amounts, and was
used as the genomic template for direct cDNA selection.
Approximately 5,000 direct selected cDNA clones were
sequenced using standard ABI 377 automated fluores-
cence sequencing methods (Applied Biosystems). Direc-
tionally cloned cDNA libraries were constructed and
screened by standard methods (Soares 1994). MZEF
(Zhang 1997), an exon-prediction program, was used
to identify putative exons that may constitute portions
of novel genes.
Mutation Analysis
PCR products were sequenced according to the stan-
dard protocol for energy-transfer primers (Amersham),
using ABI 377 sequencers. PolyPhred (Nickerson et al.
1997) was used to assemble sequence sets for viewing
with Consed (Gordon et al. 1998). All PCR primerswere
made as chimeras, to facilitate dye-primer sequencing.
The M13-21F (5′-GTA CGA CGG CCA GT-3′) and
28REV (5′-AAC AGC TAT GAC CAT G-3′) primer-
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Figure 1 BMD measurements. A plot of the hip versus spine
BMD measurements of the family with HBM is shown. Blackened
diamonds indicate individuals with the mutation, and shaded squares
indicate individuals without the mutation. The criterion used for as-
signing affection status was a sum 14 of Z scores from hip and spine,
as indicated by the diagonal line.
binding sites were included on the 5′ end of each forward
and reverse PCR primer, respectively, during synthesis.
Candidate regions were first screened in a subset of the
family with HBM, which consisted of the affected pro-
band daughter and her mother and unaffected father and
brother. Mutations that segregated exclusively with the
HBM phenotype were then re-examined in additional
members of the family. Segregating mutations in this
extended group were typed in 84 additional persons (48
individuals known to have normal BMD and 36 unre-
lated individuals [Dausset et al. 1990] with unknown
BMD). Rare mutations were subsequently examined in
the entire HBM pedigree.
Allele-Specific Oligonucleotide Analysis
Individuals were typed, using an allele-specific oligon-
ucleotide method (Dietz et al. 1991). The amplicon con-
taining the HBM mutation was amplified by PCR, using
the following primers: 5′-CCAAGTTCTGAGAAGTCC-
3′ (forward) and 5′-AATACCTGAAACCATACCTG-3′
(reverse). PCR products briefly underwent electropho-
resis on agarose gels, were blotted to nylon membranes,
and then were hybridized with radiolabeled oligo-
nucleotide probes (5′-AGACTGGGGTGAGACGC-3′
[wild-type] and 5′-CAGACTGGGTTGAGACGCC-3′
[mutant]; the mutation is underlined). The population
analyzed included 67 grandparents (most of whom
were white) from the database of the Centre d’Etude
du Polymorphisme Humain, as well as 192 white, 192
African American, 96 Hispanic, and 96 Asian
individuals.
Structural Modeling
LDLR and LRP5 sequences were aligned using the
local-alignment algorithm of Smith and Waterman
(1981) as implemented by GCG’s BestFit program. Rib-
bon diagrams were viewed using Weblab Viewer Pro
(Accelrys). The structure containing the substituted val-
ine was relaxed for 500 minimizing steps, using Dis-
cover3 as part of the Accelrys InsightII package to relax
any steric hindrances.
In Situ Hybridization
In situ hybridization to rat tibia was conducted by
Pathology Associates International. Tibias were col-
lected from two female Sprague-Dawley rats that were
6–8 wk old. The bones were sectioned, were mounted
on adhesive slides, and were hybridized with the follow-
ing probes from a unique region of the mouse LRP5
cDNA (GenBank accession number AF064984): 5′-
AGCGAGGCCACCATCCACAGG-3′ (sense primer)
and 5′-TCGCTGGTCGGCATAATCAAT-3′ (antisense
primer). Antisense and sense riboprobes were synthe-
sized using T7 and T3 RNA polymerases, respectively,
in the presence of digoxigenin-11-UTP (Boehringer-
Mannheim). A MAXIscript IVT kit (Ambion) was used
according to the manufacturer’s protocol.
Results and Discussion
In our initial genomewide scan, haplotype analysis
placed the HBM locus within a 30-cM region between
markers D11S905 and D11S937 (Johnson et al. 1997).
To narrow the genetic interval, we extended the pedigree
and genotyped additional microsatellite markers in this
region. BMDmeasurements were determined at six skel-
etal sites (spine, hip, total body, total radius, midradius,
and one-third radius). Density measurements were con-
verted to Z scores, a value that corresponds to the stan-
dard deviation by which a subject differs from the mean
value for an age- and sex-matched reference population.
As shown in figure 1, when spine Z scores are plotted
against hip Z scores, some individuals cluster into a clear
group that has a combined spine and hip Z score 14.
This index was used in subsequent analyses as the cri-
terion for determining affected status. We estimated the
probability of having a sum of hip and spine Z scores
of 14 to be ∼1% in the general population, and we used
that value to approximate the phenocopy rate in our
linkage analysis. This was based on a bivariate normal
distribution for the spinal and hip Z scores with means
of 0, variances of 1, and a correlation coefficient of .48,
as estimated from the unaffected members of the pedi-
gree. Individuals with and without HBM had mean total
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Figure 2 HBM pedigree and haplotypes of the individuals used in the genetic–linkage studies. Blackened symbols represent affected
individuals. Symbols containing “N” indicate unaffected individuals. Numbers beneath the symbols show the identification numbers, the Z
scores for the spinal and hip BMD, and the alleles for the critical markers on chromosome 11. Question marks (?) denote unknown affection
status, genotype, or phase. Untyped genotypes inferred with certainty are included in parentheses. The striped haplotype is shared by all affected
individuals; critical crossovers were identified in individuals 44 and 46. Asterisks (*) indicate the 16 additional individuals used to narrow the
region. Arrow indicates the proband.
Figure 3 Physical map of the HBM interval. STS markers derived from genes, expressed-sequence tags, microsatellites, random sequences,
and BAC end sequences are denoted above the long horizontal line. STSs derived from BAC end sequences are listed with the BAC library
address followed by L or R, for the left or right end of the clone, respectively; end sequences derived from BACs from the Genome Systems
library are indicated with GS. The two large arrows indicate the location of genetic markers that define the HBM critical region. The horizontal
lines below the STSs indicate a minimal tiling path of BAC clones that were sequenced. Open circles indicate that the marker did not amplify
from the corresponding BAC. All clones were from the CITB library except for the two preceded by an RPCI-11 prefix. A region that was
underrepresented in the library is indicated as a gap. Genes that were analyzed for mutations are shown in their approximate location at the
top of the figure. Genes with a prefix of Hs correspond to UniGene entries.
body Z scores of and , respec-4.91 1.41 0.64 1.00
tively; the mean Z score for unaffected individuals is 0.
Thus, affected members of the pedigree had a bone mass
approximately five times greater than 1 SD above the
mean of the general population. The skeletal structure
of individuals with the HBM trait in this family is com-
pletely normal, and no other unusual clinical findings
were observed in affected individuals (R. R. Recker, M.
L. Johnson, K. Davies, and S. M. Recker, unpublished
data). We are unaware of reports of comparable phe-
notypes corresponding to a generalized increase in bone
mass throughout the body. Diseases such as osteope-
trosis, pycnodysostosis (PYCD [MIM 265800]), pro-
gressive diaphyseal dysplasia (DPD1 [MIM 13100]), en-
dosteal hyperostosis (VBCH [MIM 239100]), and
melorheostosis (MIM 155950) also result in increased
bone density but are associated with detrimental effects
and usually produce localized lesions.
The pedigree used in the linkage studies is shown in
figure 2. Multipoint linkage analysis was performed us-
ing both qualitative and quantitative phenotypic defi-
nitions. The qualitative phenotype yielded a highly sig-
nificant peak LOD score of 10.1. Haplotype analysis
showed that all individuals determined to be affected,
according to this index (a sum of hip and spine Z scores
14), shared a common haplotype in the critical interval.
The quantitative analysis resulted in a peak LOD score
of 9.5 in the region of the shared haplotype and was
independent of the criterion (combined hip and spine
Z score 14) that was used in the qualitative analysis.
Haplotype analysis identified recombination events in
individuals 44 (HBM) and 46 (unaffected) that signif-
icantly refined the HBM interval (fig. 2). On the basis
of these analyses, observations for individual 44 placed
the HBM locus centromeric to marker GTC271K22,
and observations for individual 46 placed the centro-
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Figure 4 HBM mutation and domain structure of the LRP5 protein. A, Sequence traces illustrating the HBM mutation (arrow) for a
core four-member family. Identification numbers are as in figure 2. B, Domain organization of LRP5. The site of the glycine-to-valine change
that occurs in the HBM protein is indicated with an arrow. C, Similarity of LRP5 and LDLR. A ribbon representation of LDLR, in which
colors are based on homology with the first propeller (and EGF) domains of LRP5, is shown as viewed from the top. Identities are shown in
red, and similarities are shown in pink. The location of G516 of the mature LDLR protein (comparable to residue G171 in LRP5) is shown
in green. D, Simulation of the LRTP5 G171V mutation in the LDLR YWTD-EGF domain pair. The glycine at amino acid 516 of the mature
LDLR protein was replaced with a valine, and the resulting three-dimensional structures were superimposed and viewed from the side. The
wild-type structure is shown in blue with G516 in green, and the G516V mutant structure is shown in white with the V516 residue in red.
Figure 5 Northern blot analyses showing the expression ofLRP5
in various tissues.
meric boundary of the HBM locus at marker D11S987.
Thus, the HBM interval was narrowed to a 3-cM region
between markers D11S987 and GTC271K22.
A physical map spanning this critical interval was
constructed by screening BAC libraries with markers
derived from public resources and BAC insert termini
(fig. 3). To identify candidate HBM genes, genomic se-
quencing of 15 BACs from the 2-mB interval, as well
as direct cDNA selection, was performed. Figure 3 il-
lustrates the approximate location of 16 genes that were
considered as candidate HBM genes.
Comparative DNA sequencing was used to identify
mutations in the HBM candidate genes. Amplicons used
to identify mutations included exons, UTRs, splice sites,
and, in some cases, putative promoter regions. Our
strategy consisted of three stages that used different sub-
sets of the family with HBM to identify segregating
mutations and a population panel of 84 individuals to
assess allele frequencies. We assumed that, since ele-
vated BMD is rare in the general population, the causal
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Figure 6 In situ hybridization of the LRP5 gene in bone tissue.A, Localization of LRP5 transcripts in rat endosteum by in situ hybridization
with antisense and sense probes; original magnification #400. Arrow indicates bone-lining cells. B, Localization of LRP5 transcripts in rat
metaphysis and growth plate by in situ hybridization with antisense and sense probes; original magnification #100. Boxes enclose regions that
are shown at higher magnification in panel C. C, Localization of LRP5 transcripts in rat proximal metaphysis by in situ hybridization with
antisense and sense probes; original magnification #400.
mutation would not be observed at high frequency in
a random sample. A total of 231 exons were analyzed
for mutations, using this approach. On the basis of these
analyses, 146 polymorphisms were identified; 53 were
present within exons, and 93 were located in introns or
putative regulatory elements. A single mutation was
found that was present only in affected individuals of
the kindred with HBM. This rare mutation was a G-
to-T transversion in exon 3 of the LRP5 gene (Dong et
al. 1998; Hey et al. 1998; Kim et al. 1998; Twells et
al. 2001) (GenBank accession numbers AF064548 and
AAC36467 [fig. 4A]) that resulted in a glycine-to-valine
amino acid change (G171V). All affected individuals
were heterozygous for the mutation, an observation
consistent with the autosomal dominant mode of in-
heritance for the trait. To determine the allele frequency
for this mutation in the general population, an allele-
specific oligonucleotide assay was used. The population
analyzed included 275 phenotyped individuals who had
normal BMD (Z scores between 2.8 and 2.1) and
643 random individuals from an ethnically diverse
panel. Of the ∼1,000 individuals examined in the pre-
sent study, only individuals with HBM who were part
of the original kindred harbored the mutation in exon
3 of the LRP5 gene.
The protein encoded by LRP5 is a member of the
low-density lipoprotein–receptor (LDLR) gene super-
family (Hussain et al. 1999) and is most closely related
to LRP6 (Brown et al. 1998). The extracellular portions
of these two proteins contain four domains consisting
of six YWTD repeats followed by an epidermal growth
factor (EGF)–like module, and an LDLR-like ligand-
binding domain (fig. 4B). The mutation at glycine 171
occurs near the fourth YWTD repeat of the first YWTD/
EGF domain in LRP5. The second and third YWTD/
EGF repeats of LRP5 also contain glycine at the cor-
responding position, as do YWTD/EGF repeats in
LDLR, LRP6, and the mouse ortholog of LRP5, sug-
gesting that this residue is evolutionarily conserved. Re-
cently, analysis of the crystal structure of the YWTD/
EGF domain pair of the LDLR revealed that the YWTD
repeats form a six-bladed b-propeller module (Jeon et
al. 2001). To evaluate the possible impact of the HBM
mutation in this domain, we analyzed the structure of
the human LDLR YWTD-EGF domain pair (PDB 1IJQ)
by replacing the conserved glycine with valine. Figures
4C and 4D show that this residue is predicted to reside
on the surface of the protein and at the top of the pro-
peller module. Figure 4D further suggests that the gly-
cine-to-valine change would alter the local hydrophobic
environment and, thus, may affect the interaction of
LRP5 with other proteins. Interestingly, a number of
mutations in this region of the b-propeller module of
the LDLR cause familial hypercholesterolemia (Jeon et
al. 2001), confirming that this domain is important for
protein function.
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Northern blot analysis (fig. 5) revealed that LRP5
was transcribed in human bone tissue as well as in nu-
merous other tissues. Specific regions of bone were also
assessed for expression, using in situ hybridization to
rat tibia (fig. 6). LRP5 transcripts were primarily de-
tected in areas of bone involved in remodeling, including
the endosteum and trabecular bone within the meta-
physis. Hybridization was also observed to cells within
the periosteum, epiphysis, and growth plate.
Additional genetic loci segregating with a bone phe-
notype that map to 11q13 include osteoporosis pseu-
doglioma syndrome (OPS [MIM 259770]; Gong et al.
1996), autosomal recessive osteopetrosis (arOP [MIM
259700]; Heaney et al. 1998), and a quantitative trait
locus that contributes to normal variation in BMD
(Koller et al. 1998). The recent finding that deleterious
(loss of function) mutations in LRP5 cause the bone
defects seen in OPS further supports the critical role of
this gene in skeletal integrity (Gong et al. 2001). In
addition, mice deficient in LRP5 have been reported to
have low bone mass, low body weight, and abnormal
eye vascularization (Levasseur et al. 2001). Conversely,
the gain of function mutation in LRP5 that we describe
produces increased bone mass with no adverse effect on
skeletal structure. Additional compelling evidence to
support the importance of LRP5 in bone remodeling is
derived from transgenic mice that express the human
LRP5 gene containing the HBM mutation (P. Babij, W.
Zhao, C. Small, P. Reddy, P. Yaworsky, M. Bouxsein,
P. Bodine, J. Robinson, R. Moran, Y. Kharode, and F.
Bex, personal communication). These mice exhibit in-
creased trabecular and cortical bone parameters, as well
as enhanced skeletal strength. Recently, the LRP5 and
LRP6 proteins have been shown to play a role in Wnt
signaling (Pinson et al. 2000; Tamai et al. 2000; Wehrli
et al. 2000; Mao et al. 2001), which is a key pathway
involved in various developmental processes, including
skeletal differentiation (Yamaguchi et al. 1999). Further
characterization of the LRP5 protein and associated sig-
naling pathways could lead to a new paradigm for ther-
apeutics targeted to enhancing bone deposition, com-
pared with current therapies that rely on antiresorptive
agents.
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